Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics Dividend Announcement
• Spero Therapeutics announced a quarterly dividend of $0.01 per ordinary share which will be made payable on 2015-10-07. Ex dividend date: 2015-09-16
• Spero Therapeutics's trailing twelve-month (TTM) dividend yield is -%
Spero Therapeutics Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2015-09-16 | $0.01 | quarterly | 2015-10-07 |
2015-06-17 | $0.01 | quarterly | 2015-07-07 |
2015-03-18 | $0.01 | quarterly | 2015-04-07 |
2014-12-17 | $0.01 | quarterly | 2015-01-06 |
2014-09-17 | $0.01 | quarterly | 2014-10-07 |
2014-06-18 | $0.01 | quarterly | 2014-07-07 |
2014-03-19 | $0.01 | quarterly | 2014-04-07 |
2013-12-17 | $0.01 | quarterly | 2014-01-06 |
2013-09-17 | $0.01 | quarterly | 2013-10-07 |
2013-06-12 | $0.01 | quarterly | 2013-07-05 |
2013-03-20 | $0.01 | quarterly | 2013-04-05 |
2012-12-17 | $0.01 | quarterly | 2013-01-07 |
2012-09-17 | $0.01 | quarterly | 2012-10-05 |
2012-06-13 | $0.01 | quarterly | 2012-07-06 |
2012-03-20 | $0.01 | quarterly | 2012-04-04 |
2011-12-12 | $0.01 | quarterly | 2012-01-05 |
2011-09-14 | $0.01 | quarterly | 2011-10-05 |
2011-06-13 | $0.01 | quarterly | 2011-07-08 |
2011-03-22 | $0.01 | quarterly | 2011-04-04 |
2010-12-13 | $0.01 | quarterly | 2010-12-31 |
2010-09-29 | $0.01 | quarterly | 2010-10-11 |
2010-06-29 | $0.01 | quarterly | 2010-07-12 |
2010-03-30 | $0.01 | quarterly | 2010-04-11 |
Spero Therapeutics Dividend per year
Spero Therapeutics Dividend growth
Spero Therapeutics Dividend Yield
Spero Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Spero Therapeutics stock? Use our calculator to estimate your expected dividend yield:
Spero Therapeutics Financial Ratios
Spero Therapeutics Dividend FAQ
Other factors to consider when evaluating Spero Therapeutics as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Spero Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Spero Therapeutics's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Spero Therapeutics publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Spero Therapeutics distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Spero Therapeutics are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Spero Therapeutics sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Spero Therapeutics distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Spero Therapeutics declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Spero Therapeutics's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Spero Therapeutics's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.